Search Within

Harold Varmus

  1. "Sloan Kettering Institute Postdocs"
Formats
  1. Journal Article (4)
  2. Meeting Abstract (1)
Groups
  1. Department of Pathology and Laboratory Medicine (5)
  2. Sloan Kettering Institute Postdocs (5)
  3. Department of Medicine (3)
  4. GSK Faculty (3)
  5. Solid Tumor Oncology Division (3)
  6. Thoracic Oncology (3)

More Groups

People
  1. Gregory Riely (3)
  2. Mark Kris (3)
  3. Romel Somwar (3)
  4. Achim Jungbluth (2)
  5. David Shum (2)
  6. Emmet Jordan (2)

More People

Years
  1. 2018 (1)
  2. 2017 (1)
  3. 2011 (1)
  4. 2009 (1)
  5. 2005 (1)
Publications
  1. Proceedings of the National Academy of Sciences of the United States of America (2)
  2. Journal of Biomolecular Screening (1)
  3. Journal of Clinical Oncology (1)
  4. PLos Medicine (1)
Publishers
  1. National Academy of Sciences (2)
  2. American Society of Clinical Oncology (1)
  3. Public Library of Science (1)
  4. Sage Publications (1)

Results (5)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics
    Journal Article

    Fan, P. D.; Narzisi, G.; Jayaprakash, A. D.; Venturini, E.; Robine, N.; Smibert, P.; Germer, S.; Yu, H. A.; Jordan, E. J.; Paik, P. K.; more...
    Proceedings of the National Academy of Sciences of the United States of America (2018)

    Fulltext@MSK | Save
  • YES1 amplification as a mechanism of acquired resistance (AR) to EGFR tyrosine kinase inhibitors (TKIs) identified by a transposon mutagenesis screen and clinical genomic testing
    Meeting Abstract

    Fan, P. D.; Narzisi, G.; Jayaprakash, A.; Venturini, E.; Robine, N.; Smibert, P.; Germer, S.; Jordan, E.; Wang, L.; Jungbluth, A. A.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Superoxide dismutase 1 (SOD1) is a target for a small molecule identified in a screen for inhibitors of the growth of lung adenocarcinoma cell lines
    Journal Article

    Somwar, R.; Erdjument-Bromage, H.; Larsson, E.; Shum, D.; Lockwood, W. W.; Yang, G.; Sander, C.; Ouerfelli, O.; Tempst, P. J.; Djaballah, H.; more...
    Proceedings of the National Academy of Sciences of the United States of America (2011)

    Fulltext@MSK | Save
  • Identification and preliminary characterization of novel small molecules that inhibit growth of human lung adenocarcinoma cells
    Journal Article

    Somwar, R.; Shum, D.; Djaballah, H.; Varmus, H.
    Journal of Biomolecular Screening (2009)

    Fulltext@MSK | Save
  • Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain
    Journal Article

    Pao, W.; Miller, V. A.; Politi, K. A.; Riely, G. J.; Somwar, R.; Zakowski, M. F.; Kris, M. G.; Varmus, H.
    PLos Medicine (2005)

    Fulltext@MSK | Save